Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies—An Italian observational multicenter study
| Autor: | Salvatore Grosso, Pasquale Parisi, Francesco Nicita, Alberto Verrotti, Giuseppe Capovilla, Giangennaro Coppola, L. Giordano, Dario Pruna, Pasquale Striano, Federico Vigevano, S. Siliquini, E. Osanni, Oliviero Bruni, L. De Palma, Anna Luchetti, Giuseppe Gobbi, Paolo Bonanni, Alberto E. Tozzi, Vincenzo Belcastro, Maria Stella Vari, Alberto Spalice, Francesca Beccaria, Nelia Zamponi, Angelo Russo, Anna Rosati, Nicola Specchio, Raffaella Cusmai, P. De Liso, Paola Martelli, Renzo Guerrini, Lucrezia Ilvento |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty Drug Resistant Epilepsy Adolescent Pyridones Adolescents Perampanel Idiopathic generalized epilepsy 03 medical and health sciences chemistry.chemical_compound Epilepsy 0302 clinical medicine Refractory Seizures adolescents antiepileptic drug children perampanel refractory epilepsy treatment outcome Nitriles Antiepileptic drug Children Refractory epilepsy Treatment outcome Neurology Neurology (clinical) Medicine Humans 030212 general & internal medicine Child Retrospective Studies business.industry Retrospective cohort study medicine.disease Anticonvulsants Female Follow-Up Studies Italy Treatment Outcome chemistry Tolerability Concomitant Physical therapy business 030217 neurology & neurosurgery |
| Popis: | To evaluate the efficacy and tolerability of Perampanel (PER) in children and adolescents with refractory epilepsies in daily clinical practice conditions.This Italian multicenter retrospective observational study was performed in 16 paediatric epilepsy centres. Inclusion criteria were: (i) ≤18 years of age, (ii) history of refractory epilepsy, (iii) a follow-up ≥5 months of PER add-on therapy. Exclusion criteria were: (i) a diagnosis of primary idiopathic generalized epilepsy, (ii) variation of concomitant AEDs during the previous 4 weeks. Response was defined as a ≥50% reduction in monthly seizure frequency compared with the baseline.62 patients suffering from various refractory epilepsies were included in this study: 53% were males, the mean age was 14.2 years (range 6-18 years), 8 patients aged 12 years. Mean age at epilepsy onset was 3.4 years and the mean duration of epilepsy was 10.8 years (range 1-16), which ranged from 2 seizures per-month up to several seizures per-day (mean number=96.5). Symptomatic focal epilepsy was reported in 62.9% of cases. Mean number of AEDs used in the past was 7.1; mean number of concomitant AEDs was 2.48, with carbamazepine used in 43.5% of patients. Mean PER daily dose was 7.1mg (2-12mg). After an average of 6.6 months of follow-up (5-13 months), the retention rate was 77.4% (48/62). The response rate was 50%; 16% of patients achieved ≥75% seizure frequency reduction and 5% became completely seizure free. Seizure aggravation was observed in 9.7% of patients. Adverse events were reported in 19 patients (30.6%) and led to PER discontinuation in 4 patients (6.5%). The most common adverse events were behaviour disturbance (irritability and aggressiveness), dizziness, sedation and fatigue.PER was found to be a safe and effective treatment when used as adjunctive therapy in paediatric patients with uncontrolled epilepsy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|